

Statement of  
Federal  
with  
the  
branded  
generic  
health  
to help  
and  
agreements

in other words, companies lose. Ending this practice as part of  
with pay-for-delay competition, on average, 17 months longer than those without  
the generic price can be 80 percent lower. Today's study finds that settlements  
branded competitor. When there are multiple generics, usually six months after  
generic becomes available, it is generally priced 50 to 30 percent lower than its  
health care reform is the simple, effective, and straightforward way for Congress  
to help control costs. I want to thank Congressman Van Hollen, Chairman Rush,  
and Representative Kilroy for their leadership on this matter. I also want to thank  
agreements increased dramatically. In 2004, there were no pay-for-delay deals.

that he provided a statement saying why these anticompetitive agreements must be  
stopped.

The problem with these sweetheart deals is dear. Branded pharmaceutical  
companies are literally paying their generic competitors to stay off the market.

lower prices. Moreover, FTC economists estimate that these deals cost consumers \$3.5 billion a year in higher drug prices. That's why every single FTC Commissioner since 1999 – Democrats, Republicans, and an Independent – has called for an end to these unconscionable agreements. And that's why I'm so grateful that so many members of Congress are working to make stopping pay-for-delay agreements part of health care reform.